Destiny Pharma. Share Chat (DEST)

Find Your Broker

Share Name	Share Symbol	Market	Type	Share ISIN	Share Description
Destiny Pharma.	LSE:DEST	London	Ordinary Share	GB00BDHSP575	ORD GBP0.01

	Price Change	% Change	Share Price	Bid Price	Offer Price	High Price	Low Price	Open Price	Shares Traded	Last Trade
	+0.00p	+0.00%	70.50p	69.00p	72.00p	70.50p	70.50p	70.50p	0	08:00:00

Industry Sector	Turnover (m)	Profit (m)	EPS - Basic	PE Ratio	Market Cap (m)
Pharmaceuticals & Biotechnology	0.0	-3.2	-8.4	-	30.71

Destiny Pharma. Share Discussion Threads

Showing 26 to 47 of 50 messages

Chat Pages: 2 1

Date	Subject	Author	Discuss
25/10/2018 21:08	If there is any value here and China Medical bid, try and take paper. They have been a 20 bagger pour moi !	superadams	Read Full Thread Reply
25/10/2018 19:56	15p target	opodio	Read Full Thread Reply
05/10/2018 10:54	new analysis on pipeline's development and expansion, with increased fair value as a result (a multiple of current share price). Plenty of news expected in coming weeks, too. Note freely accessible here: https://www.equitydevelopment.co.uk/edreader/?ltkn=5f3dec7ebec4cbdaf80bd7d872a074b0AvbosF0F&d=%3D%3DAO4QjM	edmonda	Read Full Thread Reply
05/9/2018 10:14	https://www.edisoninvestmentresearch.com/research/report/destiny-pharma/preview/?utm_source=edison&utm_medium=EQUISOLVE_press_release&utm_campaign=DEST_04092018	mikeh30	Read Full Thread Reply
13/8/2018 12:26	Clinical progress with XF drug platform ; Recently, positive results from a blinded, placebo-controlled Phase I dermal irritancy study of lead product XF-73 in aqueous solution, showed that high concentrations of XF-73 applied topically to intact and abraded skin had a ‘similar irritancy potential to water’. Pharmacokinetic sampling confirmed that XF-73 was not absorbed into the bloodstream of volunteers, supporting the drug’s safety profile and that of other XF drugs, in treating and preventing dermal infections. The data helps to pave the way for a Phase IIb study start in a gel formulation of XF-73 in the new FDA indication for prevention of post-surgical Staphylococcus aureus infection, due to be launched on completion of a second standard dermal safety study of the gel formulation of XF-73 in H2’18. Safety study results also complement the existing strong body of data on XF-73, including its ability to rapidly kill bacteria, and so reducing the potential for AMR to develop, compared to other antimicrobials tested. The data will further assist DEST in prioritising its pipeline that contains three other preclinical candidates. Read the full note here ..https://www.equitydevelopment.co.uk/edreader/?d=%3D%3DwN1QjM	edmonda	Read Full Thread Reply
30/12/2017 10:39	Guys, I am following this only because I hold China Medical Systems Holdings which is a 26 bagger for me over the last decade. They are a very shrewd outfit but don't know whether this is good or bad for Dest.	superadams	Read Full Thread Reply
28/12/2017 12:15	Something doesn't small right?	kop202	Read Full Thread Reply
21/11/2017 10:15	Looks an AIM scam	opodio	Read Full Thread Reply
02/11/2017 11:01	Up 10p were on our way to a doubling imho i hope	albanyvillas	Read Full Thread Reply
02/11/2017 10:44	Dirty and sweet	albanyvillas	Read Full Thread Reply
02/11/2017 10:41	Nice to see the 330p price target from broker	albanyvillas	Read Full Thread Reply
02/11/2017 10:39	Houston this is Houston you read me We have launched a satellite	albanyvillas	Read Full Thread Reply
02/11/2017 10:19	Northwards horatio	albanyvillas	Read Full Thread Reply
02/11/2017 10:11	Destiny Pharma (BUY) – Prevention better than cure DEST LN (129p, TP 330p), Market Cap: £55m (Corporate Stock) Destiny Pharma’s lead programme is a novel anti-microbial targeting nasal de-colonisation of patients prior to surgery who harbour the potentially dangerous bacteria Staphylococcus aureus including the superbug MRSA. It is well documented that the majority of post-surgical infections are caused by a patient’s own bacteria principally residing in nasal passages. Consequently, new guidelines have emerged which recommend nasal de-colonisation prior to high-risk surgeries but the most widely used antibiotic suffers from significant limitations preventing widespread use. Destiny is developing a potent antimicrobial (XF-73) with several key attributes that suggest it could be optimally positioned to be the leader in a new FDA indication of prevention of post-surgical Staphylococcal infections. Clinical data has been persuasive providing a rapid bacterial kill combined with an unmatched resistance profile.	dewtrader	Read Full Thread Reply
08/10/2017 11:08	rackers - not quite ... It's a binary bet, and to a non-specialist odds would be about 9:1 against success (statistical analysis of early-stage pharma without looking under the bonnet). But someone with subject knowledge can improve his odds selectively by looking at results to date and the people involved. For example, CEO Neil Clark was involved with steering CeNeS Pharma from 20 years ago. So weeding out the less likely candidates could shorten the odds to maybe 5:1. A dozen such companies invested in over a period could produce decent profits. I wouldn't follow someone like Woodford, who seems to invest in every IPO! And I've already given my reasons for leaving it alone. however, DrMaccers (who might be in the business) has convinced me of the best strategy here.	jonwig	Read Full Thread Reply
08/10/2017 07:42	How anyone can invest in such an illiquid stock needs help.Not something any sane investor would touch I feel.	rackers1	Read Full Thread Reply
03/10/2017 20:56	This needs to get past 2b before it's investible in really. Then it'll need a lot of cash for p3.Interesting but not more at this point in time or price	drmaccers	Read Full Thread Reply
02/10/2017 13:47	At the risk of being a boor, I'll repeat my post #7 from four weeks ago: I saw the initial RNS and looked at the website. Basically their compounds appear to act so quickly that bacteria have no time to develop resistance via mutation. My immediate reaction to this was extreme scepticism. It appears to suggest that antibiotic resistant mutations happen when bacteria are stimulated by exposure to an agent. But this isn't the case: they happen purely randomly. Indeed there will already exist resistant strains, and resistant populations will develop and increase by natural selection as happens with current antibiotics. I met a biochemist last week (on holiday) whose discipline is immunology, so not quite the same, and he confirmed that my general understanding was correct. Obviously I need to do more study on this and it would be good to see if the company's research has been peer-reviewed. (A lot of these companies don't allow that.) I know their early trials have been successful, and I may be off-beam here, but I wouldn't want to invest in anything I didn't understand. I just can't find any corroborative information about their compounds (Help anyone?), and first results should be some time away. (How much?) Until then, it's unlikely the share price will do more than respond to speculative froth. A trigger will be phase results, and it's unlikely these can leak as they should be double-blind and reported immediately. When they are, how many here will understand them? More to the point, they seem to have £14m cash with a burn of £2m pa (but that will increase). At least they won't have to scramble.	jonwig	Read Full Thread Reply
02/10/2017 13:27	AIM is not a market place for the patient, and with DEST set to be relatively quiet for at least 18 months, I guess its no surprise to see the initial euphoria fade quickly.	jack jebb	Read Full Thread Reply
29/9/2017 16:16	Timberrrrr	rackers1	Read Full Thread Reply
12/9/2017 11:11	Level 2 firming	albanyvillas	Read Full Thread Reply
12/9/2017 08:30	DEST was changing hands at 240p last week Can be had at 180 now When she moves she moves	albanyvillas	Read Full Thread Reply

Chat Pages: 2 1